Clinical evidence summaries for type 2 diabetes, including glycaemic therapies, cardiovascular outcomes, kidney protection, complications, technology, obesity, and long-term safety.
An acute randomised trial in 57 sedentary adults with type 2 diabetes found a single HIIT session raised flow-mediated dilation more than moderate continuous exercise, while both lowered post-exercise glucose. PICO summary and expert commentary.
A post-hoc sub-analysis of the open-label PROCEED RCT found ipragliflozin did not improve LV diastolic function overall, with only exploratory subgroup signals. PICO summary and expert commentary.
A single-centre Korean pilot RCT of a physician-led digital education and remote-monitoring platform in type 2 diabetes, where both arms reached the same 3-month HbA1c and the early gain reversed once monitoring stopped. PICO summary and expert commentary.
A pooled analysis of three finerenone trials found a modest reduction in new-onset atrial fibrillation/flutter across the cardio-kidney-metabolic spectrum. PICO summary and expert commentary.
A small secondary analysis of the EDICT randomised trial reports that initial triple therapy was associated with slower carotid intima-media thickness progression and lower liver fat than sequential add-on therapy at matched glycaemic control. PICO summary and expert commentary.
A secondary cost-consequence and budget impact analysis of the TELE-DD trial found a nurse-led telephone program for nonadherent Type 2 diabetics with comorbid depression became cheaper per glycaemically controlled patient by 12-18 months. PICO summary and expert commentary.
A 2-centre factorial RCT in 273 Chinese adults with type 2 diabetes found the Dnurse app did not significantly improve HbA1c attainment, though systolic blood pressure fell in the app arms. PICO summary and expert commentary.
A phase 3 open-label trial in 440 Chinese adults found the dulaglutide biosimilar LY05008 met its equivalence margin for HbA1c reduction against reference dulaglutide. PICO summary and expert commentary.
A small mechanistic RCT (n=34) found ertugliflozin did not increase proximal tubular natriuresis (the primary outcome) but did reduce fluid volume and blood pressure by week 12. PICO summary and expert commentary.
Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.
© 2024-2026 Hormone Insight. All rights reserved.
